Description
About
Gulguluthikthakam Kashaya Gulika Tablet is a classical Ayurvedic tablet formulated from a blend of bitter (Tiktha) herbs and Guggulu (Commiphora mukul). It is traditionally used to pacify Vata and Kapha doshas and is highly effective in managing musculoskeletal disorders, obesity, and metabolic imbalances.
This tablet combines the benefits of Kashaya (decoction) and Guggulu, providing anti-inflammatory, detoxifying, and rejuvenating effects.
Uses
-
Relieves joint pain, stiffness, and inflammation
-
Supports treatment of arthritis, gout, and rheumatism
-
Helps in muscle weakness and Vata disorders
-
Aids in weight management and fat metabolism
-
Reduces swelling and stiffness in chronic musculoskeletal conditions
Benefits
-
Natural anti-inflammatory and analgesic properties
-
Strengthens bones, muscles, and joints
-
Supports Vata and Kapha balance
-
Improves mobility and flexibility
-
Aids in detoxification and metabolic support
-
Can be used long-term for chronic musculoskeletal disorders
Different Names in Different Languages
-
Tamil: குள்குலுதிக்தகம் கஷாய குளிகா மாத்திரை
-
Hindi: गुलगुलुथिक्तकम कश्याय गोली
-
Telugu: గుల్గులుతిక్తకం కషాయం గులికా మాత్రలు
-
Kannada: ಗುಲ್ಗುಲುತಿಕ್ತಕಂ ಕಶಾಯ ಗುಲಿಕಾ ಟ್ಯಾಬ್ಲೆಟ್
-
Malayalam: ഗുള്ഗുലുതിക്തകം കഷായ ഗുളിക
-
English: Gulguluthikthakam Kashaya Tablet
Key Ingredients
-
Guggulu (Commiphora mukul) – anti-inflammatory, joint support
-
Tiktha herbs (bitter herbs) – detoxifying, Kapha-Vata pacifier
-
Dashamoola – Vata-pacifying and analgesic
-
Other Kashaya herbs – enhance anti-inflammatory and rejuvenating action
Dosage & Administration
-
Adults: 1–2 tablets twice daily with warm water or honey
-
Best taken after meals
-
Follow Ayurvedic physician guidance for chronic or severe conditions
Precautions
-
Not recommended during pregnancy or lactation without physician advice
-
People with gastric ulcers or acidity should consult a doctor
-
Avoid overdose – may cause mild gastric discomfort
-
Store in a cool, dry place

























Reviews
There are no reviews yet.